Open menu
  • logo
  • ExportsExports
  • Products
    • Search for Product
      • Product Name

        Keyword Search

    • Featured Products
        • PARVEXON

          PARVEXON

        • PARVEXON PLUS

          PARVEXON PLUS

  • News
  • Library
  • Facilities
  • Regions
  • Contacts

News

Pictured at the Joint Arab Irish Chamber of Commerce (JAICC) 25th Anniversary celebration at the Shelbourne Hotel, Dublin, today, were (l-r) Ahmad Younis, Secretary General, JAICC, Gavin Lee, International Business Manager and Siobhan Moyna, Bimeda. Acknowledging 25 companies who have traded through the chamber since its inception in 1987, the chamber presented an excellence in Trading certificate to Bimeda, highlighting the hard work and commitment of their companies who have consistently serviced their customers in the Arab markets.

New Environmental Flea Product in Europe

Wednesday, 04 April 2012 14:25
FLEE is the safest alternative to pesticide use. Click here to learn more.
“Your safe solution for Selenium deficient herds.”  One injection provides a prolonged rise, lasting up to 12 months, in the selenium status in cattle. Please contact Bimeda for more details.

Bimeda Launches Parvexon Plus

Wednesday, 04 April 2012 14:08
Parvexon Plus, new East coast fever treatment being launched on the following dates: South Sudan18th April Kenya20th April Zambia23rd April

Parvexon

Wednesday, 14 March 2012 13:56
Theileriosis kills about three million cattle in Africa, Mid-East and Asia each year. There are two main forms, East Coast fever (ECF) and Tropical Theileriosis (TT). Both diseases are transmitted by the bite of ticks. Mortality rates approach 100% among susceptible cattle, particularly of European dairy breeds. Two drugs, parvaquone and buparvaquone, are available to treat the disease. Cure rates are high if early and accurate diagnosis is made. Effective live vaccines have been developed but they are not widely available. So far, killed and molecular vaccines have been ineffective. Acaricidal dips and sprays are still the most widely used…

Bimeda in Chinese JV

Monday, 10 October 2011 21:08
Bimeda has forged a joint venture firm in Shijiazhuang in northern China to develop and manufacture veterinary and animal health products for the Chinese and Asian regional market. The 50-50 joint venture between Bimeda and Shijiazhuang Rainbow Laboratories will initially provide product stability and raw materials testing for the pharmaceutical industry. The state of the art facility operates to the principals of Good Laboratory practise (GLP) & is ISO 9001 accredited. FDA approval of the Laboratory is pending but is expected imminently. It will be the initial platform for expected further investment by Bimeda in the Chinese market. Employing twenty analysts…

Bimeda In Kenya

Monday, 10 October 2011 21:06
Bimeda acquires Assia Animal Health, formally a subsidiary of Phibro Animal Health Inc. Bimeda has relocated its East African headquarters to Kenya.   Today Bimeda's East African market share is the largest in the animal health pharmaceutical sector.

New Commercial Veterinarian Joins Bimeda Team

Saturday, 08 October 2011 18:49
Bimeda are delighted to announce the appointment of Mr. Padraig Hyland as Commercial Veterinarian to the expanding team. Padraig will be vital to the company's future growth and expansion. He will ensure that Bimeda is positioned as a leader in the area of animal health. Mr. Tom Kelleher, Head of Sales and Marketing, Ireland and UK, welcomed Mr. Hyland to the company and said, "At Bimeda we are committed to providing and extensive range of top quality animal health products. We are determined to be market leaders in providing cost effective animal health solutions. Padraig brings considerable practical experience and…
Bimeda Holdings Plc (Bimeda) has announced the acquisition of a majority shareholding in Mogivet Farmaceutica SA (Mogivet), an Animal Health Company based in Monte Mor, Sao Paulo, Brazil. Mogivet manufactures and markets a wide range of products to the Animal Health Sector in Brazil.  Mogivet has sales of $17m and employs 105 people in R&D, Manufacturing and Sales. Growth in the Latin American Market is a strategic objective for Bimeda and this Investment gives it access to the Brazilian Market, as well as manufacturing capability in the Region.  
Page 2 of 2

We use cookies, just to track visits to our website, we store no personal details. Read our privacy policy